Explore the frontier of life sciences and healthcare innovation. From breakthrough therapeutics and longevity research to the deep tech investments shaping tomorrow's treatments, discover the trends and breakthroughs redefining global health.
Five-year data from the KEYNOTE-942 trial shows Moderna and Merck's personalized mRNA cancer vaccine (intismeran autogene) cut melanoma recurrence by 49% when combined with Keytruda — and the effect held from year three to year five.
Eighty percent of the human proteome is classified as undruggable. The surfaces are smooth. The binding pockets are missing. Conventional small molecules slide off them like water off wax. In the first half of 2026 alone, more than €8 million in seed and early-stage capital flowed into a single
NUS researchers built a self-training platform that strengthens lab-grown muscle tissue around the clock, powering OstraBot to a record 467 mm/min — the fastest skeletal muscle-driven biohybrid robot ever reported.
The FDA needs patient data to approve drugs. Rare-disease patients have the least data. That contradiction is why synthetic data is now gaining regulatory traction — and changing the economics of orphan-drug development.
An AI copilot for robotic surgery completed its first live clinical demonstration in Ghent. The surgical robotics market reached $18.3B, with AI-enabled systems capturing 35% of new installations. At least four research groups now field working prototypes.
CRISPR and AI-driven gene-target discovery are converging with NASA and startup-built space agriculture systems, creating a new frontier at the intersection of biotech and deep-space food autonomy.
The four metrics that institutional biotech funds actually use, the three red flags that kill deals at Series A, and how to verify a founder's claims without relying on the pitch deck.
Isomorphic Labs raised $2.1B to scale its IsoDDE AI drug design engine toward first-in-human clinical trials by end of 2026.